Noah Richardson
@Noah_Onc
Followers
42
Following
275
Media
1
Statuses
39
IU Heme/Onc Chief Fellow | GU Onc | Melanoma | RNA Therapeutics
Joined September 2023
RT @nabiladra: Tour de force by Larry Einhorn going over Pitfalls in the Management of Metastatic GCT and wisdom from over 50 years of expe….
0
10
0
Appreciate all the support and guidance from a friend and mentor @nabiladra over the years. It’s been a wonderful #ASCO2025 and looking forward to joining a great GU group! @SalousTareq @JenniferKingMD @IUCancerCenter
0
0
11
RT @oncology_bg: The most practice changing trial from #ASCO25 is now live on @NEJM .If this was a drug, this would be approved today. Glob….
0
303
0
RT @nabiladra: Indiana University reception at #ASCO2025 . Proud to work with a fantastic group of past, present, and future colleagues @IU….
0
8
0
RT @IUHemOnc: Congrats to chief fellow @Noah_Onc for their @ConquerCancerFd Young Investigator Award investigating novel prostate cancer th….
0
7
0
RT @IUuro: Management of testis cancer course at #AUA25 led by IU team @ClintCaryMD @nabiladra and Dr. Masterson! @IUCancerCenter
https://t….
0
4
0
RT @IUHemOnc: As a leading institution in the management of germ cell tumors, @IUHemOnc fellows work with @IUCancerCenter faculty leading t….
0
5
0
RT @DocMattCampbell: Standing room only for GCT session. Happy to see the enthusiasm to review new data and trial landscape. Time to fini….
0
8
0
RT @nabiladra: Thoughtful discussion by @ClintCaryMD of @IUuro regarding surgery in early metastatic seminoma. @IUCancerCenter @TestesCance….
0
12
0
RT @Timothee_MD: No post-recurrence data is so concerning. again, the comparison is informative: .➡️AMBASSADOR (adj pembro), accrual till….
0
1
0
Among patients who had been alive and progression-free at 3 years (1/3 of the IPI/Nivo arm), 10-year melanoma-specific survival was 96%. Incredible! 🏆.
Presented at #ESMO24:. Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared with 20 months with ipilimumab alone. Full CheckMate 067 trial results:
0
0
2
RT @HTawbi_MD: Update on NADINA by @MinkeLucas consistent & impressive DMFS data w neoadjuvant low dose ipi+nivo, benefit for RFS carrying….
0
4
0
RT @HTawbi_MD: Expertly presented by @ProfGLongMIA impressive data updating the INMC pooled analysis with 818 pts confirming that MPR w ICI….
0
4
0
Great opportunity!.
We are still accepting applications for our combined Hem/Onc & Palliative/Hospice medicine fellowship. It is a 3 year program eligible for the Hematology, Medical Oncology and Palliative Care boards. @ASCO @IUHPMFellows .
0
0
1
RT @DrBetofMDPhD: @OncoAlert Look at those curves!!! 67% relative risk reduction! Favors ipi/nivo in all subgroups. 59% major pathological….
0
2
0
RT @ahmadalhader: 🚨 NADINA is positive. NADINA is the first phase 3 trial that evaluates neoadj ICI against SOC in melanoma, and is also th….
0
1
0
RT @JournalCancer: New findings from @IUCancerCenter researchers indicate that salvage HDCT and PBSCT is an active combination in patients….
0
7
0
RT @OncoAlert: Dear Colleagues,.The @OncoAlert 🚨Network Presents OUR Picks of.TOP 🔟Abstracts to be Presented at #ASCO24 for #Melanoma. This….
0
16
0
RT @Timothee_MD: New post of the "Friday's GEM" section of the Drug Development Letter !. A seminal trial in breast cancer led by @GeorgeSl….
0
1
0
RT @tompowles1: The NADINA trial of neoadjuvant ipi/nivo vs adjuvant nivo in melanoma is a plenary #ASCO24 . Shorter periods of therapy in….
0
20
0